Literature DB >> 24509127

High-throughput molecular profiling of a P-cadherin overexpressing breast cancer model reveals new targets for the anti-cancer bacterial protein azurin.

Nuno Bernardes1, Ana Sofia Ribeiro2, Sofia Abreu3, André F Vieira2, Laura Carreto4, Manuel Santos4, Raquel Seruca2, Joana Paredes2, Arsenio M Fialho5.   

Abstract

Azurin is a bacterial protein from Pseudomonas aeruginosa which exerts an inhibitory activity in cancer cells. In P-cadherin-overexpressing models, a bad prognosis marker in breast cancer increasing invasion and other malignant features, azurin decreases the invasion of cancer cells. We performed a microarray analysis to compare the expression profile of azurin treated cells with different P-cadherin expression levels. Azurin up-regulated apoptosis mediated by p53 protein, endocytosis and vesicle-mediated transport. In the contrary, in invasive MCF-7/AZ.Pcad cells, azurin decreased the expression of genes associated with cell surface receptors and signal transduction, as well as biological adhesion. Further, azurin decreased adhesion of cells to proteins from the extracellular matrix (ECM) and altered protein expression of integrins α6, β4 and β1 and interfered with the ability of these cells to form mammospheres. Altogether, our results further enlighten the anti-cancer effects mediated by azurin in P-cadherin overexpression breast cancer models.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Azurin; Breast cancer; Integrin; P-cadherin; cDNA microarrays

Mesh:

Substances:

Year:  2014        PMID: 24509127     DOI: 10.1016/j.biocel.2014.01.023

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  9 in total

1.  Bacterial azurin in potential cancer therapy.

Authors:  Ananda M Chakrabarty
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534

Review 2.  Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives.

Authors:  Zheng Pang; Meng-Di Gu; Tong Tang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

3.  Conditioned Medium From Azurin-Expressing Human Mesenchymal Stromal Cells Demonstrates Antitumor Activity Against Breast and Lung Cancer Cell Lines.

Authors:  Marília Silva; Gabriel Amaro Monteiro; Arsenio M Fialho; Nuno Bernardes; Cláudia Lobato da Silva
Journal:  Front Cell Dev Biol       Date:  2020-07-09

4.  Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.

Authors:  Nuno Bernardes; Sofia Abreu; Filomena A Carvalho; Fábio Fernandes; Nuno C Santos; Arsénio M Fialho
Journal:  Cell Cycle       Date:  2016-04-20       Impact factor: 4.534

Review 5.  Anticancer Actions of Azurin and Its Derived Peptide p28.

Authors:  Fan Huang; Qianhui Shu; Zhaojie Qin; Jianglin Tian; Zhengding Su; Yongqi Huang; Meng Gao
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

6.  Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs.

Authors:  Nuno Bernardes; Ana Rita Garizo; Sandra N Pinto; Bernardo Caniço; Catarina Perdigão; Fábio Fernandes; Arsenio M Fialho
Journal:  Cell Cycle       Date:  2018-08-04       Impact factor: 4.534

Review 7.  P-cadherin and the journey to cancer metastasis.

Authors:  André Filipe Vieira; Joana Paredes
Journal:  Mol Cancer       Date:  2015-10-06       Impact factor: 27.401

Review 8.  Perturbing the Dynamics and Organization of Cell Membrane Components: A New Paradigm for Cancer-Targeted Therapies.

Authors:  Nuno Bernardes; Arsenio M Fialho
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

Review 9.  Bacterial proteins and peptides in cancer therapy: today and tomorrow.

Authors:  Ananda M Chakrabarty; Nuno Bernardes; Arsenio M Fialho
Journal:  Bioengineered       Date:  2014-05-29       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.